Compare Mesoblast Limited (MESO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Williams-Sonoma, Inc. — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Williams-Sonoma, Inc. trades at $220.04 (market cap $26.30B). The key difference: Williams-Sonoma, Inc. is far larger — about 12.1× Mesoblast Limited's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WSM | |
|---|---|---|
Market Cap | $2.17B | $26.30B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $240.06 |
52-Week Low | $12.88 | $168.64 |
Enterprise Value | $2.17B | $27.14B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Williams-Sonoma (WSM) trades at $223.34, down 2.22% today, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with 13.81% net margins and 54.01% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent earnings beats and consistent dividend payments highlight operational strength amid competitive retail pressures.
WSM presents a mixed outlook with solid fundamentals but faces revenue headwinds and high valuation multiples. Analyst consensus is cautious with 60.72% hold ratings and a $215.22 price target below current levels. Key risks include consumer discretionary spending volatility and execution challenges in maintaining premium positioning against competitors like RH.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
